HCLL™ Transfusion software passes rigorous testing processes and receives Authorization to Operate (ATO) certification in rollout to 68 global military health sites.
LENEXA, KS June 4, 2012 –Mediware® Information Systems, Inc. announced today that the company’s HCLL Transfusion software has earned the Authorization to Operate (ATO) certification from the U.S. Department of Defense, a critical step in the implementation of enterprise software in the US Military Health System (MHS). HCLL™ Transfusion was licensed last spring for use at 68 MHS sites worldwide. Mediware’s LifeTrak® Donor software, which was contracted for use at 28 global sites in late 2010, was awarded ATO status in July, 2011. Implementation efforts for both contracts continue to progress.
“Achieving ATO status from the U.S. Department Defense is a significant achievement, one that highlights the robust and secure nature of our software,” said Thomas Mann, Mediware’s president and chief executive officer. “Throughout the certification process, the DOD performs intense testing to analyze any possible impact the software may have on the security and scalability of the MHS network. I’m pleased that both products have now received certification and that we can look forward to the next steps in these global engagements.”
Mediware is involved in two separate initiatives to modernize the blood management information systems used by the MHS. The first contract award included Mediware’s LifeTrak software, which was selected to support the full spectrum of blood donor center functions. This includes managing blood donations, blood donor screening and the associated record keeping for military blood donors, their dependent donors and other civilian donors in the United States, abroad and in theaters of operations. It also includes donor screening and registration, as well as blood manufacturing processes such as donor collection, component preparation, testing, labeling, shipping and reporting. The new system will share information among individual centers; create lookback (i.e., blood product traceability) across blood centers throughout the MHS; and share information in standard formats with other MHS IT systems.
The second contract award included Mediware’s HCLL Transfusion software, which will allow MHS facilities to utilize common clinical processes and share patient and inventory data across the various branch operations throughout the world. The HCLL software is currently used by more than 350 hospitals, including many of the largest academic medical centers and hospital networks. The software provides customers more than 60 clinical checks to help ensure the right blood is transfused to the right patient and enables hospitals and hospital networks with powerful inventory management capabilities to manage blood products across multiple locations and facilities. HCLL is 510(k) cleared as a medical device by the U.S. Food and Drug Administration.
Both initiatives are part of a MHS Global Blood Initiative that will eventually also include KnowledgeTrak to provide integrated training and compliance management, and InSight to provide blood management specific performance dashboards. In both projects Mediware is providing software and services as a subcontractor with a consortium of other selected vendors who are providing implementation and consulting services associated with the project.
For more information about these products, please visit the blood management solutions section of Mediware’s website.
About MediwareMediware delivers interoperable best-of-breed software systems that improve efficiencies and address safety concerns, enabling healthcare organizations to improve care processes while decreasing costs. Core Mediware solutions include blood management technologies for hospitals and blood centers; cell therapy solutions for cord blood banks, cancer treatment centers and research facilities; medication management solutions for hospitals, behavioral health facilities, infusion and specialty pharmacy providers; and business intelligence-based performance management solutions for clinical, regulatory and financial aspects of the broader healthcare market. For more information about Mediware products and services, visit our website at https://www.mediware.com/
JAC is the UK’s leading medicine management systems specialist, with the largest installed base of Electronic Prescribing and Medicines Administration systems in UK hospitals. With over 20 years experience within medicines management, JAC provides pharmacy stock control, e-prescribing and medicines administration as a single integrated solution along with associated services and third-party interfaces. JAC’s systems are used in more than half of all NHS trusts in England as well as sites in Scotland, Wales, Northern Ireland, Ireland and South Africa.
About the Cyto Management System
The CMS software is a comprehensive ‘closed loop’ solution for managing chemotherapy treatments that is focused on reducing errors, streamlining patient management and optimizing efficiency through the care treatment process. Consisting of five main components, CMS manages the prescription of chemotherapy for the physician, the planning of the chemotherapy for the patient, the planning for the preparation of the chemo therapy, the preparation of cytotoxic drugs and all the other sterile preparations. CMS is designed to be highly interoperable and includes multi-lingual capabilities to allow the software to be easily configured for international distribution.
Certain statements in this press release may constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as the same may be amended from time to time (the “Act”) and are intended to be covered by the safe harbor created thereby. Such forward-looking statements are not necessarily based on historical facts and involve known and unknown risks, uncertainties and other factors which may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward looking statements. These risk and uncertainties include but are not limited to those disclosed in the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company does not intend to, and undertakes no obligation to, update forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time. The Company regularly posts important information to the investor relations section of its website.